XtalPi (HKG:2228) reported a loss attributable to equity holders of the company of 251.9 million yuan for the first half compared with a profit of 82.8 million yuan a year earlier.
The biotech company's loss per share stood at 0.06 yuan, compared with earnings per share of 0.02 yuan in the year-ago period, according to a Wednesday filing with the Hong Kong Exchange.
Revenue decreased to 393.6 million yuan for the six months ended June 30 from 517.1 million yuan.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.